vs
Side-by-side financial comparison of COASTAL FINANCIAL CORP (CCB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $138.0M, roughly 1.3× COASTAL FINANCIAL CORP). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -5.8%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -3.6%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CCB vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $138.0M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 12.4% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | -5.8% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.84 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $138.0M | $196.9M | ||
| Q3 25 | $144.7M | $179.5M | ||
| Q2 25 | $119.4M | $181.1M | ||
| Q1 25 | $139.5M | $168.9M | ||
| Q4 24 | $146.5M | $187.3M | ||
| Q3 24 | $151.1M | $168.6M | ||
| Q2 24 | $135.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $13.6M | $5.4M | ||
| Q2 25 | $11.0M | $-4.8M | ||
| Q1 25 | $9.7M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.5M | $-143.5M | ||
| Q2 24 | $11.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 12.4% | 1.2% | ||
| Q3 25 | 12.4% | 3.5% | ||
| Q2 25 | 12.0% | 4.7% | ||
| Q1 25 | 8.4% | 1.2% | ||
| Q4 24 | 11.7% | 13.2% | ||
| Q3 24 | 10.8% | -82.8% | ||
| Q2 24 | 11.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 9.4% | 3.0% | ||
| Q2 25 | 9.2% | -2.7% | ||
| Q1 25 | 7.0% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.9% | -85.1% | ||
| Q2 24 | 8.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.84 | $0.05 | ||
| Q3 25 | $0.88 | $0.12 | ||
| Q2 25 | $0.71 | $-0.11 | ||
| Q1 25 | $0.63 | $0.10 | ||
| Q4 24 | $0.95 | $0.38 | ||
| Q3 24 | $0.97 | $-3.11 | ||
| Q2 24 | $0.84 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $491.0M | $653.9M |
| Total Assets | $4.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $491.0M | $693.1M | ||
| Q3 25 | $475.3M | $727.2M | ||
| Q2 25 | $461.7M | $757.8M | ||
| Q1 25 | $449.9M | $798.5M | ||
| Q4 24 | $438.7M | $778.3M | ||
| Q3 24 | $331.9M | $749.6M | ||
| Q2 24 | $316.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.7B | $1.3B | ||
| Q3 25 | $4.6B | $1.3B | ||
| Q2 25 | $4.5B | $1.5B | ||
| Q1 25 | $4.3B | $1.6B | ||
| Q4 24 | $4.1B | $1.6B | ||
| Q3 24 | $4.1B | $1.5B | ||
| Q2 24 | $4.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $254.6M | — |
| Free Cash FlowOCF − Capex | $246.1M | — |
| FCF MarginFCF / Revenue | 178.3% | — |
| Capex IntensityCapex / Revenue | 6.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $436.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $254.6M | $43.7M | ||
| Q3 25 | $59.0M | $60.8M | ||
| Q2 25 | $66.0M | $12.0M | ||
| Q1 25 | $71.7M | $35.5M | ||
| Q4 24 | $259.8M | $33.1M | ||
| Q3 24 | $62.6M | $53.9M | ||
| Q2 24 | $72.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $246.1M | $43.5M | ||
| Q3 25 | $57.4M | $57.0M | ||
| Q2 25 | $64.0M | $9.3M | ||
| Q1 25 | $68.9M | $26.9M | ||
| Q4 24 | $249.9M | $31.0M | ||
| Q3 24 | $60.2M | $49.8M | ||
| Q2 24 | $69.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 178.3% | 22.1% | ||
| Q3 25 | 39.7% | 31.7% | ||
| Q2 25 | 53.6% | 5.1% | ||
| Q1 25 | 49.4% | 15.9% | ||
| Q4 24 | 170.6% | 16.6% | ||
| Q3 24 | 39.8% | 29.6% | ||
| Q2 24 | 51.3% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 0.1% | ||
| Q3 25 | 1.2% | 2.2% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 2.0% | 5.1% | ||
| Q4 24 | 6.8% | 1.1% | ||
| Q3 24 | 1.6% | 2.4% | ||
| Q2 24 | 1.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | 11.20× | ||
| Q2 25 | 5.99× | — | ||
| Q1 25 | 7.37× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 6.22× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
